


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED
MAR 27 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
lu	A1	4,529,561	07/16/85	Hunt, C.A. <i>et al.</i>	264	4.3	
	A2	4,920,016	04/24/90	Allen, T.M. <i>et al.</i>	424	450	
	A3	5,013,556	05/07/91	Woodle, M.C. <i>et al.</i>	424	450	
	A4	5,225,212	07/06/93	Martin, F.J. <i>et al.</i>	424	450	
	A5	5,230,882	07/27/93	Unger, E.C.	424	9	
	A6	5,374,548	12/20/94	Caras, I.W.	424	450	
	A7	5,484,894	01/16/96	Woiszwilllo, J.E.	530	410	
	A8	5,514,670	05/07/96	Friedman, D. <i>et al.</i>	514	2	
	A9	5,534,241	07/09/96	Torchilin, V.P. <i>et al.</i>	424	9.321	
	A10	5,542,935	08/06/96	Unger, E.C. <i>et al.</i>	604	190	
	A11	5,543,390	08/06/96	Yatvin, M.B. <i>et al.</i>	514	2	
	A12	5,545,569	08/13/96	Grainger, D.J. <i>et al.</i>	436	518	
	A13	5,552,156	09/03/96	Burke, T.G.	424	450	
	A14	5,567,410	10/22/96	Torchilin, V.P. <i>et al.</i>	424	9.4	
	A15	5,573,934	11/12/96	Hubbell, J.A. <i>et al.</i>	435	177	
	A16	5,578,709	11/26/96	Woiszwilllo, J.E.	530	410	
	A17	5,580,575	12/03/96	Unger, E.C. <i>et al.</i>	424	450	
	A18	5,580,853	12/03/96	Sytkowski, A.J.	514	8	

RECEIVED
MAR 05 2002
TECH CENTER 1600/2900

EXAMINER


Kuh

DATE CONSIDERED

5/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Growth
164

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED
 MAR 27 2002
 TECH CENTER
 600/2900

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
lu	A19	5,585,112	12/17/96	Unger, E.C. <i>et al.</i>	424	450	
	A20	5,587,149	12/24/96	Punto, L. <i>et al.</i>	424	59	
	A21	5,589,453	12/31/96	Greve, J.M. <i>et al.</i>	514	8	
	A22	5,595,722	01/21/97	Grainger, D.J. <i>et al.</i>	424	9.2	
	A23	5,612,027	03/18/97	Galin, M.A. <i>et al.</i>	424	78.04	
	A24	5,633,226	05/27/97	Owen, A.J. <i>et al.</i>	514	2	
lu	A25	5,635,187	06/03/97	Bathurst, I.C. <i>et al.</i>	424	195.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
lu	B1	0082311	05/22/82	JP	—	—	ABSTRACT ONLY	
	B2	WO 93/20802	10/28/93	WIPO	—	—		
	B3	WO 95/27496	10/19/95	WIPO	—	—		
	B4	WO 97/35560	10/02/97	WIPO	—	—		
lu	B5	WO 97/35561	10/02/97	WIPO	—	—		

EXAMINER

lu

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

TECH CENTER 1600/2900

MAR 05 2002

RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C1	Alessandrini, F. <i>et al.</i> , "Vasoactive Intestinal Peptide Enhances Lung Preservation," <i>Transplantation</i> , 56(4):964-973 (October, 1993).
	C2	Alexandridis, P. <i>et al.</i> , "Temperature Effects of Structural Properties of Pluronic P104 and F108 PEO-PPO-PEO Block Copolymer Solutions," <i>Langmuir</i> , 11:1468-1476 (1995).
	C3	Alkan-Onyuksel, H. <i>et al.</i> , "A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol," <i>Pharmaceutical Research</i> , 11(2):206-212 (1994).
	C4	Alkan-Onyuksel, H. <i>et al.</i> , "Development of Inherently Echogenic Liposomes as an Ultrasonic Contrast Agent," <i>Journal of Pharmaceutical Sciences</i> , 85(5):486-490 (May, 1996).
	C5	Allen, T.M. <i>et al.</i> , "Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System," <i>Federation European Biochemical Societies</i> , 223(1):42-46 (October, 1987)
	C6	Allen, T.M. <i>et al.</i> , "Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo," <i>Biochimica et Biophysica Acta</i> , 1066:29-36 (1991).
	C7	Almgren, M. <i>et al.</i> , "Self-aggregation and phase behavior of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymers in aqueous solution," <i>Colloid Polym Sci.</i> , 273:2-15 (1995).
	C8	Artwohl, J.F. <i>et al.</i> , "Initial Characterization of Hamsters with Spontaneous Hypertension," <i>FASEB J.</i> , 10:A628 (1996).
	C9	Avidor, R. <i>et al.</i> , "VIP-mRNA is increased in hypertensive rats," <i>Brain Research</i> , 503:304-307 (1989).
lu	C10	Bangham, A.D. <i>et al.</i> , "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids," <i>J. Mol. Biol.</i> , 13:238-252 (1965).

EXAMINER

luke

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C11	Beaumier, P.L. <i>et al.</i> , "Effect of Liposome Dose on the Elimination of Small Unilamellar Sphingomyelin/Cholesterol Vesicles from the Circulation," <i>Research Communications in Chemical Pathology and Pharmacology</i> , 39(2):277-289 (February, 1983).
	C12	Beaumier, P.L. <i>et al.</i> , "Effects of Liposome Size on the Degradation of Bovine Brain Sphingomyelin/Cholesterol Liposomes in the Mouse Liver," <i>Biochimica et Biophysica Acta</i> , 731:23-30 (1983).
	C13	Bedu-Addo, F.K. <i>et al.</i> , "Interaction of Polyethyleneglycol-Phospholipid Conjugates with Cholesterol-Phosphatidylcholine Mixtures: Sterically Stabilized Liposome Formulations," <i>Pharmaceutical Research</i> , 13(5):718-724 (1996)
	C14	Berisha, H. <i>et al.</i> , "Vasoactive intestinal peptide prevents lung injury due to xanthine oxidase," <i>Am. J. Physiol.</i> , 259:L151-L155 (1990).
	C15	Bodanszky, M. <i>et al.</i> , "A Preferred Conformation in the Vasoactive Intestinal Peptide (VIP). Molecular Architecture of Gastrointestinal Hormones," <i>Bioorganic Chemistry</i> , 3:133-140 (1974).
	C16	Bolin, D.R. <i>et al.</i> , "Design and Development of a Vasoactive Intestinal Peptide Analog as a Novel Therapeutic for Bronchial Asthma," <i>Biopolymers, (Peptide Science)</i> 37:57-66 (1995).
	C17	Carey, M.C. <i>et al.</i> , "Micelle Formation by Bile Salts," <i>Arch Inter. Med.</i> , 130:506-527 (October, 1972).
	C18	Chiba, K. <i>et al.</i> , "Interaction Between Lipids and Bovine Brain Calmodulin: Lysophosphatidylcholine-Induced Conformation Change," <i>Life Science</i> , 47:953-960 (1990).
lu	C19	Damrongchai, N. <i>et al.</i> , "Calcium Responsive Two-Dimensional Molecular Assembling of Lipid-Conjugated Calmodulin," <i>Bioconjugate Chem.</i> , 6:264-268 (1995).

EXAMINER

Kuh

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

RECEIVED

TECH CENTER 1600 2900

TECH CENTER 1600 2900

MAR 05 2002

MAR 27 2002

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C20	DeGrado, W.F. <i>et al.</i> , "Induction of Peptide Conformation at Apolar/Water Interfaces. 1. A Study with Model Peptides of Defined Hydrophobic Periodicity," <i>J. Am. Chem. Soc.</i> , 107:7684-7689 (1985).
C21	Demos, S.M. <i>et al.</i> , "In Vitro Targeting of Antibody-Conjugated Echogenic Liposomes for Site-Specific Ultrasonic Image Enhancement," <i>Journal of Pharmaceutical Sciences</i> , 86(2):167-171 (February, 1997).
C22	Fournier, A. <i>et al.</i> , "Synthesis, Conformational Studies and Biological Activities of VIP and Related Fragments," <i>Peptides</i> 5:169-177 (1984).
C23	Frase, L.L. <i>et al.</i> , "Cardiovascular Effects of Vasoactive Intestinal Peptide in Healthy Subjects," <i>Am. J. Cardio.</i> , 60:1356-1361 (1987).
C24	Fry, D.C. <i>et al.</i> , "Solution Structure of an Analogue of Vasoactive Intestinal Peptide As Determined by Two-Dimensional NMR and Circular Dichroism Spectroscopies and Constrained Molecular Dynamics," <i>Biochemistry</i> , 28:2399-2409 (1989).
C25	Gabizon, A. <i>et al.</i> , "Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors," <i>Proc. Natl. Acad. Sci. (USA)</i> , 85:6949-6953 (September, 1988).
C26	Gao, X. <i>et al.</i> , "Loop diuretics attenuate bradykinin-induced increase in clearance of macromolecules in the oral mucosa," <i>J. Appl. Physiol.</i> , 80(3):818-823 (1996).
C27	Gao, X. <i>et al.</i> , "Vasoactive Intestinal Peptide Encapsulated in Liposomes: Effects on Systemic Arterial Blood Pressure," <i>Life Sciences</i> , 54(15): PL247-PL252 (1994).
C28	Gozes, I. <i>et al.</i> , "VIP: Molecular Biology and Neurobiological Function," <i>Molecular Neurobiology</i> , 3:201-236 (1989).
C29	Gozes, I. <i>et al.</i> , "Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A Novel VIP Analog for Noninvasive Impotence Treatment," <i>Endocrinology</i> , 134(5):2121-2125 (1994).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

RECEIVED

MAR 27 2002

TECH CENTER 1600/2900

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

W	C30	Gozes, I. <i>et al.</i> , "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive Intestinal Peptide Receptors," <i>J. Pharmacology Experimental Therapeutics</i> , 273(1):161-167 (1995).
	C31	Gregoriadis, G. <i>et al.</i> , "Fate of Protein-Containing Liposomes Injected into Rats: An Approach to the Treatment of Storage Diseases," <i>Eur. J. Biochem.</i> 24:485-491 (1972).
	C32	Gregoriadis, G. <i>et al.</i> , "Liposomes in Drug Delivery: Clinical, Diagnostic and Ophthalmic Potential," <i>Drugs</i> , 45(1):15-28 (1993).
	C33	Haghjoo, K. <i>et al.</i> , "Solution Structure of Vasoactive Intestinal Polypeptide (11-28)-NH ₂ , a Fragment with Analgesic Properties," <i>Peptide Research</i> , 9(6):327-331 (1996).
	C34	Hamed, M.M. <i>et al.</i> , "Behavior of Amphipathic Helices on Analysis via Matrix Methods, with Application to Glucagon, Secretin, and Vasoactive Intestinal Peptide," <i>Biopolymers</i> , 22:1003-1021 (1983).
	C35	Hirata, Y. <i>et al.</i> , "Functional Receptors For Vasoactive Intestinal Peptide In Cultured Vascular Smooth Muscle Cells From Rat Aorta," <i>Biochemical Biophysical Research Communications</i> , 132(3):1079-1087 (November, 1985).
	C36	Hjelm, R.P. Jr. <i>et al.</i> , "Organization of Phosphatidylcholine and Bile Salt in Rodlike Mixed Micelles," <i>J. Phys. Chem.</i> , 96(21):8653-8661 (1992).
	C37	Hökfelt, T., "Neuropeptide in Perspective: The Last Ten Years," <i>Neuron</i> , 7:867-879 (1991).
✓	C38	Houbre, D. <i>et al.</i> , "The Interactions of the Brain-specific Calmodulin-binding Protein Kinase C Substrate, Neuromodulin (GAP 43), with Membrane Phospholipids," <i>Journal Biological Chemistry</i> , 266(11):7121-7131 (April, 1991).
W	C39	Hristova, K. <i>et al.</i> , "Effect of Bilayer Composition on the Phase Behavior of Liposomal Suspensions Containing Poly(ethylene glycol)- Lipids," <i>Macromolecules</i> , 28(23):7793-7799 (1995).

EXAMINER

W

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 600/2900

MAR 27 2002

RECEIVED

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lw	C40	Hristova, K. <i>et al.</i> , "Phase Behavior of a Lipid/Polymer-Lipid Mixture in Aqueous Medium," <i>Macromolecules</i> , 28:991-1002 (1995).
	C41	Hwang, K.J., "Liposome Pharmacokinetics," in <i>Liposomes from Biophysics to Therapeutics</i> , Ostro, M.J. (Ed.), Marcel Dekker, Inc., New York, pp. 109-156 (1987).
	C42	Kaiser, E.T. <i>et al.</i> , "Peptides with Affinity for Membranes," <i>Ann. Rev. Biophys. Biophysical Chem.</i> , 16:561-581 (1987).
	C43	Kates, M., in <i>Laboratory Techniques in Biochemistry and Molecular Biology: Techniques in Lipidology Isolation, Analysis and Identification of Lipids</i> , Work, T.S. <i>et al.</i> , (Eds.) North-Holland/American Elsevier, New York, New York, USA, pp. 354-356 (1972).
	C44	Kedar, E. <i>et al.</i> , "Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes," <i>Journal of Immunotherapy</i> , 16:47-59 (1994).
	C45	Kenworthy, A.K. <i>et al.</i> , "Structure and Phase Behavior of Lipid Suspensions Containing Phospholipids with Covalently Attached Poly(ethylene glycol)," <i>Biophysical Journal</i> , 68:1903-1920 (May, 1995).
	C46	Kirby, C. <i>et al.</i> , "Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes," <i>Biotechnology</i> , pp. 979-984 (November 1984).
	C47	Kirby, C. <i>et al.</i> , "Effect of the Cholesterol Content of Small Unilamellar Liposomes on their Stability <i>in vivo</i> and <i>in vitro</i> ," <i>Biochem. J.</i> , 186:591-598 (1980).
	C48	Klibanov, A.L. <i>et al.</i> , "Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target," <i>Biochimica Biophysica Acta</i> , 1062:142-148 (1991).
lw	C49	Klibanov, A.L. <i>et al.</i> , "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes," <i>FEBS Lett.</i> , 268(1):235-237 (July, 1990).

EXAMINER

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C50	Krejs, G.J., "Effect of Vasoactive Intestinal Peptide in Man," <i>Am. N.Y. Acad. Sci.</i> , 527:501-507 (1988).
	C51	Lasic, D. <i>et al.</i> , <i>Stealth Liposomes</i> , Lasic, D. <i>et al.</i> , (Eds.), CRC Press, Inc., Boca Raton, FL, pp. 1-289 (1995).
	C52	Litzinger, D.C. <i>et al.</i> , "Effect of Liposome Size on the Circulation Time and Intraorgan Distribution of Amphipathic Poly(ethylene glycol)-Containing Liposomes," <i>Biochimica et Biophysica Acta</i> , 1190:99-107 (1994).
	C53	Liu, D. <i>et al.</i> , "Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM ₁ -containing liposomes," <i>Biochimica et Biophysica Acta</i> , 1104:95-101 (1992).
	C54	Lutz, E.M. <i>et al.</i> , "The VIP ₂ receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide," <i>FEBS Lett</i> , 334(1):3-8 (November, 1993).
	C55	MacDonald, R.C. <i>et al.</i> , "Small-Volume Extrusion Apparatus for Preparation of Large, Unilamellar Vesicles," <i>Biochimica et Biophysica Acta</i> , 1061:297-303 (1991).
	C56	Malhotra, R.K. <i>et al.</i> , "Vasoactive Intestinal Polypeptide and Muscarine Mobilize Intracellular Ca ²⁺ through Breakdown of Phosphoinositides to Induce Catecholamine Secretion," <i>Journal of Biological Chemistry</i> , 263(5):2123-2126 (1988).
	C57	Maruyama, K. <i>et al.</i> , "Effect of Molecular Weight in Amphipathic Polyethyleneglycol on Prolonging the Circulation Time of Large Unilamellar Liposomes," <i>Chem. Pharm. Bull.</i> , 39(6):1620-1622 (1991).
lu	C58	Mayhan, W.G. <i>et al.</i> , "Acetylcholine Induces Vasoconstriction in the Microcirculation of Cardiomyopathic Hamsters: Reversal by L-Arginine," <i>Biochemical and Biophysical Research Communications</i> , 184(3):1372-1376 (May, 1992).

EXAMINER

ku

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 27 2002
TECH CENTER 1600/2930

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

6	C59	Mayhan, W.G. <i>et al.</i> , "The Effect of Altering the External Calcium Concentration and a Calcium Channel Blocker, Verapamil, on Microvascular Leaky Sites and Dextran Clearance in the Hamster Cheek Pouch," <i>Microvascular Research</i> , 28:159-179 (1984).
	C60	Morice, A. <i>et al.</i> , "Vasoactive Intestinal Peptide Causes Bronchodilatation and Protects Against Histamine-Induced Bronchoconstriction in Asthmatic Subjects," <i>Lancet</i> , 262(8361):1225-1227 (November, 1983).
	C61	Muller, J. <i>et al.</i> , "VIP as a Cell-Growth and Differentiation Neuromodulator Role in Neurodevelopment," <i>Molecular Neurobiology</i> , 10:115-134 (1995).
	C62	Muranushi, N. <i>et al.</i> , "Effect Of Fatty Acids And Monoglycerides On Permeability Of Lipid Bilayer," <i>Chemistry and Physics of Lipids</i> , 28:269-279 (1981).
	C63	Musso, G.F. <i>et al.</i> , "Development of Helix-Based Vasoactive Intestinal Peptide Analogues: Identification of Residues Required for Receptor Interaction," <i>Biochemistry</i> , 27:8174-8181 (1988).
	C64	Nivaggioli, T. <i>et al.</i> , "Fluorescence Probe Studies of Pluronic Copolymer Solutions as a Function of Temperature," <i>Langmuir</i> , 11(3):730-737 (1995).
	C65	Noda, Y. <i>et al.</i> , "Partitioning of Vasoactive Intestinal Polypeptide into Lipid Bilayers," <i>Biochimica et Biophysica Acta</i> , 1191:324-330 (1994).
	C66	Nucci, M.L. <i>et al.</i> , "The Therapeutic Value of Poly(ethylene glycol)-Modified Proteins," <i>Advanced Drug Delivery Reviews</i> , 6:133-151 (1991).
	C67	Ollerenshaw, S. <i>et al.</i> , "Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with Asthma," <i>New England Journal of Medicine</i> , 320:1244-1248 (May, 1989).
	C68	Omary, M.B. <i>et al.</i> , "Identification of Nuclear Receptors for VIP on a Human Colonic Adenocarcinoma Cell Line," <i>Science</i> , 238:1578-1581 (1987).

EXAMINER

kru

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 27 2002
TECH CENTER 1600/2300

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C69	Patel, M. <i>et al.</i> , "Simplified Preparation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," <i>Proceedings of International Controlled Release Bioactive Materials</i> , 24:913-914 (1997).
	C70	Patel, M., "Study of Interactions Between Vasoactive Intestinal Peptide and Phospholipid Vesicles and Micelles," Masters Thesis, University of Illinois at Chicago, Chicago, Illinois (1997).
	C71	Paul, S. <i>et al.</i> , "Regulatory Aspects of the Vasoactive Intestinal Peptide Receptor in Lung," <i>Ann. N.Y. Acad. Sci.</i> , 527:282-295 (1988).
	C72	Paul, S., "Vasoactive Intestinal Peptide: Its Interactions with Calmodulin and Catalytic Antibodies," <i>Neurochem. Int.</i> , 23(3):197-214 (1993).
	C73	Raud, J., "Intravital Microscopic Studies on Acute Mast Cell-Dependent Inflammation," <i>Acta Physiologica Scandinavica Supplementum</i> 578:1-58 (1989).
	C74	Robinson, R.M. <i>et al.</i> , "Lipid-Induced Conformational Changes in Glucagon, Secretin, and Vasoactive Intestinal Peptide," <i>Biopolymers</i> , 21(6):1217-1228 (June 1982).
	C75	Rorstad, O.P. <i>et al.</i> , "Selectivity for Binding of Peptide Analogs to Vascular Receptors for Vasoactive Intestinal Peptide," <i>Molecular Pharmacology</i> , 37:971-977 (1990).
	C76	Rubinstein, I. <i>et al.</i> , "Tissue Angiotensin I-Converting Enzyme Activity in Spontaneously Hypertensive Hamsters," <i>Biochemical and Biophysical Research Communications</i> , 183(3):1117-1123 (March, 1992).
	C77	Rubinstein, I. <i>et al.</i> , "Cigarette Smoke Extract Attenuates Endothelium-Dependent Arteriolar Dilatation In Vivo," <i>Am. J. Physiol.</i> , 261 (Heart Circ. Physiol. 30):H1913-H1918 (1991).
lu	C78	Rubinstein, I., "L-Arginine Dilates Cheek Pouch Arterioles in Hamsters with Hereditary Cardiomyopathy but not in Controls," <i>J. Lab. Clin. Med.</i> , 125:313-318 (1995).

EXAMINER

lu

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 27 2003
TECH CENTER 1600/2000

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263

INFORMATION DISCLOSURE STATEMENT

Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

lu	C79	Said, S.I., "Vasoactive Intestinal Peptide (VIP) and Related Peptides as Anti-Asthma and Anti-Inflammatory Agents," <i>Biomedical Research</i> , 13(Supplement 2):257-262 (1992).
	C80	Said, S.I., "Vasoactive Intestinal Polypeptide (VIP): Current Status," <i>Peptides</i> , 5:143-150 (1984).
	C81	Said, S.I., "Vasoactive Intestinal Polypeptide: Biological Role in health and Disease," <i>Trends Endocrinology Metab.</i> , 2(3):107-112 (1991).
	C82	Saletu, B. <i>et al.</i> , "Comparative Bioavailability Studies with a New Mixed-micelles Solution of Diazepam Utilizing Radioreceptor Assay, Psychometry and EEG Brain Mapping," <i>International Clinical Psychopharmacology</i> , 3:287-323 (1988).
	C83	Sansom, S.P., "The Biophysics of Peptide Models of Ion Channels," <i>Prog. Biophys. Molec. Biol.</i> , 55:139-235 (1991).
	C84	Séjourné <i>et al.</i> , "Development of a Bioactive Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," <i>Pharm. Res.</i> , 13(Suppl. 9):S-95 (1996).
	C85	Séjourné, F. <i>et al.</i> , "Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo," <i>American Journal of Physiology</i> , 273:R287-R292 (1997).
	C86	Séjourné, F. <i>et al.</i> , "Development of a Novel Bioactive Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," <i>Pharmaceutical Research</i> , 14(3):362-365 (1997).
	C87	Shiraga, H. <i>et al.</i> , "Inhibition of calmodulin-dependent myosin light-chain kinase by growth-hormone-releasing factor and vasoactive intestinal peptide," <i>Biochem. J.</i> , 300:901-905 (1994).
lu	C88	Smiley, J.D., "Southwestern Internal Medicine Conference: The Many Faces of Scleroderma," <i>American Journal Medical Sciences</i> , 304:319-333 (1992).

EXAMINER

lu

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 27 2002
TECH CENTER 1600/200

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C89	Soloviev, A.I., <i>et al.</i> , "Phospholipid Vesicles (Liposomes) Restore Endothelium-Dependent Cholinergic Relaxation in Thoracic Aorta from Spontaneously Hypertensive Rats," <i>J. Hypertension</i> , 11:623-627 (1993)
C90	Sreedharan, S.P. <i>et al.</i> , "Human Vasoactive Intestinal Peptide Receptors Expressed By Stable Transfectants Couple To Two Distinct Signaling Pathways," <i>Biochemical Biophysical Research Communications</i> , 203(1):141-148 (August, 1994).
C91	Stallwood, D. <i>et al.</i> , "Identity of a Membrane-bound Vasoactive Intestinal Peptide-binding Protein with Calmodulin," <i>Journal of Biological Chemistry</i> , 267(27):19617-19621 (September, 1992).
C92	Suzuki, H. <i>et al.</i> , "Encapsulation of VIP into Liposomes Restores Vasorelaxation in Hypertension in Situ," <i>American Journal of Physiology</i> , 271(Heart Circ. Physiol., 40):H282-H287 (1996).
C93	Suzuki, H., <i>et al.</i> , "Encapsulation of Vasoactive Intestinal Peptide into Liposomes: Effects on Vasodilation <i>in Vivo</i> ," <i>Life Sciences</i> , 57(15):1451-1457 (1995).
C94	Suzuki, H. <i>et al.</i> , "Neutral Endopeptidase Modulates VIP-Induced Vasodilation in Hamster Cheek Pouch Vessels In Situ," <i>Am. J. Physiol.</i> , 271(2 pt. 2):R393-397 (August, 1996).
C95	Szucs, M., <i>et al.</i> , "Lyophilization and Rehydration of Polymer-coated Lipid Vesicles Containing a Lipophilic Chelator in the Presence of Sucrose: Labeling with ^{99m} Tc and Biodistribution Studies," <i>Nucl. Med. Biol.</i> , 22(2):263-268 (1995).
C96	Theriault, Y. <i>et al.</i> , "Structural Determination of the Vasoactive Intestinal Peptide by Two-Dimensional H-NMR Spectroscopy," <i>Biopolymers</i> , 31:459-464 (1991).
C97	Torchilin, V.P. <i>et al.</i> "Polymers on the Surface of Nanocarriers: Modulation of Carrier Properties and Biodistribution," <i>Polymer Science</i> , 36(11):1585-1598 (1994).
C98	Torchilin, V.P., "Polymer-coated long-circulating microparticulate pharmaceuticals," <i>J. Microencapsulation</i> , 15(1):1-19 (1998).

EXAMINER

KME

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
TECH CENTER 1600/2900
MAR 27 2003

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

l	C99	Trubetskoy, V. <i>et al.</i> , "Micellar Solubilization of Poorly Soluble or Amphiphilic Substances Using Polyoxyethylene-Lipid Conjugates," <i>Proceedings of International Symposium on Controlled Release Bioactive Materials</i> , 22:452-453 (1995).
	C100	Trubetskoy, V.S. <i>et al.</i> , "Stable Polymeric Micelles: Lymphangiographic Contrast Media for Gamma Scintigraphy and Magnetic Resonance Imaging," <i>Acad. Radiol.</i> , 3:232-238 (1996).
	C101	Trubetskoy, V.S. <i>et al.</i> , "Polyethyleneglycol based micelles as carriers of therapeutic and diagnostic agents," <i>S.T.P. Pharma Sciences</i> , 6(1):79-86 (1996).
	C102	Trubetskoy, V.S. <i>et al.</i> , "Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents," <i>Advanced Drug Delivery Reviews</i> , 16:311-320 (1995).
	C103	Watala, C., <i>et al.</i> , "Melittin-Induced Alterations in Dynamic Properties of Human Red Blood Cell Membranes," <i>Chem-Biol. Interactions</i> , 82:135-149 (1992).
	C104	Weissig, V. <i>et al.</i> , "A Micellar Delivery System For Dequalinium," <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i> , 25:415-416 (1998).
	C105	Weissig, V. <i>et al.</i> , "Accumulation of Protein-Loaded Long-Circulating Micelles and Liposomes in Subcutaneous Lewis Lung Carcinoma in Mice," <i>Pharmaceutical Research</i> , 15(10):1552-1556 (1998).
	C106	Weissig, V. <i>et al.</i> , "Micellar Delivery System For Dequalinium-A Lipophilic Cationic Drug With Anticarcinoma Activity," <i>Journal of Liposome Research</i> , 8(3):391-400 (1998).
	C107	Woodle, M.C. <i>et al.</i> , "Improved Long Circulating (Stealth®) Liposomes Using Synthetic Lipids," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> , 17:77-78 (1990).
W	C108	Woodle, M.C. <i>et al.</i> , "Sterically stabilized liposomes," <i>Biochimica et Biophysica Acta</i> , 113:171-199 (1992).

EXAMINER

KMK

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

RECEIVED

MAR 27 2002

TECH CENTER 1600/2000

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/36928Serial No.
09/995,263Applicant
Onyuksel, H. *et al.*Filing Date
November 27, 2001Group
1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C109	Woodle, M.C. <i>et al.</i> , "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes," <i>Biochimica et Biophysica Acta</i> , 1105:193-200 (1992).
C110	Woodle, M.C. <i>et al.</i> , "Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat," <i>Pharmaceutical Research</i> , 9(2):260-265 (1992).
C111	Yokoyama, M. <i>et al.</i> , "Preparation of adriamycin-conjugated poly(ethylene glycol)-poly (aspartic acid) block copolymer," <i>Makromol Chem. Rapid Commun.</i> , 8:431-435 (1987).
C112	Zareie, H.M. <i>et al.</i> , "STM images of PDLA-PEG copolymer micelles," <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 112:19-24 (1996).
C113	Zia, H. <i>et al.</i> , "Breast Cancer Growth Is Inhibited by Vasoactive Intestinal Peptide (VIP) Hybrid, a Synthetic VIP Receptor Antagonist," <i>Cancer Research</i> , 56:3486-3489 (August, 1996).
C114	Zorn, N.E. <i>et al.</i> , "Vasoactive Intestinal Peptide (VIP) Activation of Nuclear Protein Kinase C in Purified Nuclei of Rat Splenocytes," <i>Biochemical Pharmacology</i> , 40:2689-2694 (1990).

RECEIVED

MAR 27 2002

TECH CENTER 1600/2900

EXAMINER

Law

DATE CONSIDERED

5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.